Wells Fargo
NRIX icon

Wells Fargo’s Nurix Therapeutics NRIX Stock Holding History

Wells Fargo’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$870K Sell
56,137
-61,717
-52% -$1.02M ﹤0.01% 3819
2025
Q4 		$2.24M Buy
117,854
+57,150
+94% +$821K ﹤0.01% 3347
2025
Q3 		$561K Buy
60,704
+8,573
+16% +$89K ﹤0.01% 4223
2025
Q2 		$594K Buy
52,131
+9,301
+22% +$101K ﹤0.01% 4020
2025
Q1 		$509K Buy
42,830
+3,551
+9% +$59.4K ﹤0.01% 4088
2024
Q4 		$740K Sell
39,279
-1,524
-4% -$34.9K ﹤0.01% 3913
2024
Q3 		$917K Buy
40,803
+15,454
+61% +$350K ﹤0.01% 3597
2024
Q2 		$529K Buy
25,349
+4,182
+20% +$65.1K ﹤0.01% 3879
2024
Q1 		$311K Buy
21,167
+2,011
+10% +$21.6K ﹤0.01% 4198
2023
Q4 		$198K Sell
19,156
-14,890
-44% -$102K ﹤0.01% 4474
2023
Q3 		$268K Sell
34,046
-5,967
-15% -$54.5K ﹤0.01% 4176
2023
Q2 		$400K Buy
40,013
+6,583
+20% +$67.1K ﹤0.01% 4112
2023
Q1 		$297K Buy
33,430
+31,730
+1,866% +$331K ﹤0.01% 4192
2022
Q4 		$18.7K Sell
1,700
-926
-35% -$11.2K ﹤0.01% 5292
2022
Q3 		$34K Sell
2,626
-334
-11% -$5.29K ﹤0.01% 5126
2022
Q2 		$38K Sell
2,960
-7,766
-72% -$88K ﹤0.01% 5150
2022
Q1 		$150K Sell
10,726
-10,230
-49% -$182K ﹤0.01% 5126
2021
Q4 		$607K Buy
20,956
+6,402
+44% +$194K ﹤0.01% 4511
2021
Q3 		$437K Buy
14,554
+14,234
+4,448% +$439K ﹤0.01% 4734
2021
Q2 		$9K Sell
320
-13,495
-98% -$396K ﹤0.01% 6178
2021
Q1 		$430K Sell
13,815
-33,692
-71% -$1.27M ﹤0.01% 4768
2020
Q4 		$1.56M Buy
47,507
+12,261
+35% +$406K ﹤0.01% 3668
2020
Q3 		$1.23M Buy
+35,246
New +$888K ﹤0.01% 3695

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wells Fargo's NRIX Position: Q1 2026 in Review

Wells Fargo reduced its Nurix Therapeutics (NRIX) stake by 52% in Q1 2026, selling an estimated $1.02M and leaving 56,137 shares worth $870K. The position accounts for ﹤0.01% of the portfolio, ranked #3819.

Wells Fargo first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $2.24M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Wells Fargo held 56,137 shares of Nurix Therapeutics worth $870K as of Q1 2026.
  • Wells Fargo sold 61,717 Nurix Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Nurix Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3819 holding.
  • Wells Fargo first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Wells Fargo's Nurix Therapeutics position peaked at $2.24M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.